McKinley Carter Wealth Services Inc. Has $820,000 Position in Danaher Co. (NYSE:DHR)

McKinley Carter Wealth Services Inc. cut its stake in shares of Danaher Co. (NYSE:DHR) by 2.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,948 shares of the conglomerate’s stock after selling 86 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Danaher were worth $820,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DHR. Tsfg LLC lifted its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at about $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the 1st quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $267.99 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a 50 day moving average price of $270.53 and a two-hundred day moving average price of $259.65. The firm has a market capitalization of $198.50 billion, a P/E ratio of 45.42, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. Equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Barclays boosted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Stephens started coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective on the stock. Leerink Partners upped their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Finally, Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.